{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 16,
  "pageCount": 32,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "why_now",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The diagram illustrates a decision-tree process based on clinical trial outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/16",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Signal-seeking study in patients with BPD enables decision-making on advancing navacaprant to proceed to pivotal program in BPD",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f23e7691-050d-4133-af5b-74147951e549",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "Evidence from the navacaprant Phase 2 study and the NIMH-sponsored FASTMAS demonstrate the utility of KOR pharmacology for depression and anhedonia symptoms. Anhedonia is a highly prevalent and clinically relevant symptom in BPD. Navacaprant studies have demonstrated meaningful improvements in anhedonia symptoms in patients with moderate-to-severe MDD. The primary endpoint for evaluating efficacy in bipolar depression is MADRS. Currently approved therapies have significant limitations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5920cc34-7ceb-41d3-8a85-72661a40ceff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "Strong Rationale for Efficacy in Bipolar Depression (BPD):",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "032ed84e-00fc-4b61-9745-5b396c61e273",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Potential for Broad Applicability of Navacaprant Beyond MDD Includes Bipolar Depression",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a36866c1-c4c6-495e-af15-e938d88ebd0c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "decision-tree",
      "slug": null,
      "matchId": "730b6b98-41af-4b5c-b7ee-74457733f388",
      "evidence": "The diagram maps clinical outcomes to specific next-step decisions.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}